<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00420927</url>
  </required_header>
  <id_info>
    <org_study_id>M06-810</org_study_id>
    <secondary_id>2006-004139-31</secondary_id>
    <nct_id>NCT00420927</nct_id>
  </id_info>
  <brief_title>Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis</brief_title>
  <acronym>OPTIMA</acronym>
  <official_title>A Multicenter, Randomized, Double-Period, Double âˆ’ Blind Study to Determine the Optimal Protocol for Treatment Initiation With Methotrexate and Adalimumab Combination Therapy in Patients With Early Rheumatoid Arthritis (OPTIMA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compared the safety and efficacy of combination therapy with adalimumab plus
      methotrexate (MTX) to that of MTX monotherapy (i.e., placebo plus MTX) in subjects with early
      rheumatoid arthritis (RA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a 78-week, multicenter, randomized, double-blind, double-treatment period study
      designed to compare the safety and efficacy of adalimumab and MTX with placebo and MTX in
      subjects with early RA. Subjects were randomized to receive adalimumab 40 mg every other week
      (eow) or placebo subcutaneous injections in combination with orally administered MTX for 26
      weeks (Period 1). All subjects in all arms received open-label MTX weekly throughout the
      study (both Period 1 and Period 2).

      At Weeks 22 and 26, subjects were assessed for achievement of low disease activity, defined
      as a DAS28 score below 3.2. DAS28 is a measure of RA disease activity calculated using the
      number of tender and swollen joints (out of a total of 28), C-reactive protein level (CRP, a
      blood marker of inflammation), and the patient's global assessment of disease activity
      (indicated by marking a 10 cm line between very good and very bad). Subjects who achieved low
      disease activity at Week 22 and 26 in the adalimumab arm at the end of Period 1 were
      randomized to receive MTX monotherapy (placebo and MTX) or combination therapy (adalimumab
      and MTX) in a 1:1 ratio for the duration of Period 2 (52 weeks, i.e., to Week 78 of the
      study). Subjects achieving low disease activity at Week 22 and 26 in the placebo arm (MTX
      monotherapy) at the end of Period 1 continued to receive MTX monotherapy (and placebo
      injections in a blinded fashion) for the duration of Period 2. Subjects failing to achieve
      low disease activity at Week 22 and 26 at the end of Period 1 received open-label combination
      therapy during Period 2 regardless of treatment assignment in Period 1.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Low Disease Activity (DAS28 Less Than 3.2) and No Radiographic Progression From Baseline (Change in mTSS Less Than or Equal to 0.5) at Week 78, Arm 2 vs. Arm 4</measure>
    <time_frame>Week 78</time_frame>
    <description>The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07, with scores below 3.2 indicating low disease activity. For the modified Total Sharp score (mTSS), x-rays of hand/wrist and feet joints are scored for erosions (0 to 5) and joint space narrowing (0 to 4). The erosion score and the narrowing score are added to determine the total score, which ranges from 0 (no damage) to 448.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Low Disease Activity (DAS28 Less Than 3.2) and No Radiographic Progression From Baseline (Change in mTSS Less Than or Equal to 0.5) at Week 78, Arm 2 vs. Arm 1</measure>
    <time_frame>Week 78</time_frame>
    <description>The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07, with scores below 3.2 indicating low disease activity. For the modified Total Sharp score (mTSS), x-rays of hand/wrist and feet joints are scored for erosions (0 to 5) and joint space narrowing (0 to 4). The erosion score and the narrowing score are added to determine the total score, which ranges from 0 (no damage) to 448.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With DAS28 Low Disease Activity (DAS28 Less Than 3.2) at Week 78</measure>
    <time_frame>Week 78</time_frame>
    <description>The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07. A DAS28 less than 2.6 indicates clinical remission, DAS28 2.6 to 3.2 indicates low disease activity, DAS28 3.2 to less than 5.1 indicates moderate disease activity, and DAS28 of 5.1 or greater indicates high disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With DAS28 Remission (DAS28 Less Than 2.6) at Week 78</measure>
    <time_frame>Week 78</time_frame>
    <description>The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07. A DAS28 less than 2.6 indicates clinical remission, DAS28 2.6 to 3.2 indicates low disease activity, DAS28 3.2 to less than 5.1 indicates moderate disease activity, and DAS28 of 5.1 or greater indicates high disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS Less Than or Equal to 0.5) at Week 78</measure>
    <time_frame>Week 78</time_frame>
    <description>For the modified Total Sharp score (mTSS), x-rays of hand/wrist and feet joints are scored for erosions (0 to 5) and joint space narrowing (0 to 4). The erosion score and the narrowing score are added to determine the total score, which ranges from 0 (no damage) to 448. An increase in mTSS from baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 78</measure>
    <time_frame>Week 78</time_frame>
    <description>Subjects were responders if they had greater than or equal to 20% improvement in tender joint count; greater than or equal to 20% improvement in swollen joint count; and greater than or equal to 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and acute phase reactant (C-reactive protein).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 78</measure>
    <time_frame>Week 78</time_frame>
    <description>Subjects were responders if they had: greater than or equal to 50% improvement in tender joint count; greater than or equal to 50% improvement in swollen joint count; and greater than or equal to 50% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and acute phase reactant (C-reactive protein).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Meeting American College of Rheumatology 70% (ACR70) Response Criteria at Week 78</measure>
    <time_frame>Week 78</time_frame>
    <description>Subjects were responders if they had: greater than or equal to 70% improvement in tender joint count; greater than or equal to 70% improvement in swollen joint count; and greater than or equal to 70% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and acute phase reactant (C-reactive protein).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DAS28 Score at Week 78</measure>
    <time_frame>Baseline to Week 78</time_frame>
    <description>The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07. A DAS28 less than 2.6 indicates clinical remission, DAS28 2.6 to 3.2 indicates low disease activity, DAS28 3.2 to less than 5.1 indicates moderate disease activity, and DAS28 of 5.1 or greater indicates high disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Clinical Disease Activity Index (CDAI) Low Disease Activity (CDAI Less Than or Equal to 10) at Week 78</measure>
    <time_frame>Week 78</time_frame>
    <description>The CDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, and physician's global assessment of disease activity. Scores range from 0 to 76.0, with a higher score reflecting worsening disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Simplified Disease Activity Index (SDAI) Low Disease Activity (SDAI Less Than or Equal to 11) at Week 78</measure>
    <time_frame>Week 78</time_frame>
    <description>The SDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, physician's global assessment of disease activity, and acute phase reactant (C-reactive protein). Scores range from 0.1 to 86.0, with a higher score reflecting worsening disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Clinical Disease Activity Index (CDAI) Remission (CDAI Less Than or Equal to 2.8) at Week 78</measure>
    <time_frame>Week 78</time_frame>
    <description>The CDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, and physician's global assessment of disease activity. Scores range from 0 to 76.0, with a higher score reflecting worsening disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Simplified Disease Activity Index (SDAI) Remission (SDAI Less Than or Equal to 3.3) at Week 78</measure>
    <time_frame>Week 78</time_frame>
    <description>The SDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, physician's global assessment of disease activity, and acute phase reactant (C-reactive protein). Scores range from 0.1 to 86.0, with a higher score reflecting worsening disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDAI Score at Week 78</measure>
    <time_frame>Baseline to Week 78</time_frame>
    <description>The CDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, and physician's global assessment of disease activity. Scores range from 0 to 76.0, with a higher score reflecting worsening disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SDAI Score at Week 78</measure>
    <time_frame>Baseline to Week 78</time_frame>
    <description>The SDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, physician's global assessment of disease activity, and acute phase reactant (C-reactive protein). Scores range from 0.1 to 86.0, with a higher score reflecting worsening disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Synovitis Score According to the Rheumatoid Arthritis Magnetic Resonance Imaging (RA MRI) Scoring System (RAMRIS) at Week 78</measure>
    <time_frame>Baseline to Week 78</time_frame>
    <description>Synovitis was assessed using high-field magnetic resonance imaging (MRI) of the hand and wrist. Images were read and scored according to the Outcomes Measures in Rheumatology Clinical Trials' Rheumatoid Arthritis MRI Scoring System (OMERACT RAMRIS). Synovitis in the wrist and finger joints in the most affected hand was scored from 0 (normal) to 3 (severe), for a maximum total score of 21.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5) and Normal Function (HAQ-DI Less Than 0.5) at Week 78</measure>
    <time_frame>Week 78</time_frame>
    <description>In the Health Assessment Questionnaire Disability Index (HAQ-DI), participants rated their ability to perform daily tasks on a scale of 0 (without any difficulty) to 3 (unable to do). A mean score of 0-1 represents mild to moderate functional disability, 1-2 represents moderate to severe, 2-3 severe to very severe disability. For the modified Total Sharp score (mTSS), x-rays of hand/wrist and feet joints are scored for erosions (0 to 5) and joint space narrowing (0 to 4). The erosion score and the narrowing score are added to determine the total score, which ranges from 0 (no damage) to 448.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5), Normal Function (HAQ-DI Less Than or Equal to 0.5), and ACR70 Response at Week 78</measure>
    <time_frame>Week 78</time_frame>
    <description>In the Health Assessment Questionnaire Disability Index (HAQ-DI), a score of 0-1 represents mild to moderate, 1-2 moderate to severe, 2-3 severe to very severe disability. The modified Total Sharp score (mTSS) ranges from 0 (no joint damage) to 448 (worst joint damage). American College of Rheumatology 70% (ACR70) response indicates at least 70% improvement in tender and swollen joint counts and at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; HAQ-DI; and C-reactive protein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5), Normal Function (HAQ-DI Less Than 0.5), and DAS28 Remission (DAS28 Less Than 2.6) at Week 78</measure>
    <time_frame>Week 78</time_frame>
    <description>In the Health Assessment Questionnaire Disability Index (HAQ-DI), a score of 0-1 represents mild to moderate, 1-2 moderate to severe, 2-3 severe to very severe disability. The modified Total Sharp score (mTSS) ranges from 0 (no joint damage) to 448 (severe joint damage). The Disease Activity Score (DAS28) ranges from 0.49 to 9.07, with scores less than 2.6 indicating clinical remission.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1032</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>ADA+MTX/PBO+MTX (Arm 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADA+MTX/ADA+MTX (Arm2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADA+MTX/OL ADA+MTX (Arm 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA + MTX during Period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBO+MTX/PBO+MTX (Arm 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBO+MTX/OL ADA+MTX (Arm 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>adalimumab</intervention_name>
    <description>Adalimumab 40 mg/0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)</description>
    <arm_group_label>ADA+MTX/PBO+MTX (Arm 1)</arm_group_label>
    <arm_group_label>ADA+MTX/ADA+MTX (Arm2)</arm_group_label>
    <arm_group_label>ADA+MTX/OL ADA+MTX (Arm 3)</arm_group_label>
    <arm_group_label>PBO+MTX/OL ADA+MTX (Arm 5)</arm_group_label>
    <other_name>Humira</other_name>
    <other_name>D2E7</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Methotrexate 2.5 mg tablets administered orally once a week starting at 7.5 mg/week with dose escalation (weekly or every other week) by 2.5 mg intervals to 20 mg/week.</description>
    <arm_group_label>ADA+MTX/PBO+MTX (Arm 1)</arm_group_label>
    <arm_group_label>ADA+MTX/ADA+MTX (Arm2)</arm_group_label>
    <arm_group_label>ADA+MTX/OL ADA+MTX (Arm 3)</arm_group_label>
    <arm_group_label>PBO+MTX/PBO+MTX (Arm 4)</arm_group_label>
    <arm_group_label>PBO+MTX/OL ADA+MTX (Arm 5)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo for adalimumab 0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)</description>
    <arm_group_label>ADA+MTX/PBO+MTX (Arm 1)</arm_group_label>
    <arm_group_label>PBO+MTX/PBO+MTX (Arm 4)</arm_group_label>
    <arm_group_label>PBO+MTX/OL ADA+MTX (Arm 5)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Subject must be 18 or older and in good health

          -  Subject must meet the definition of early rheumatoid arthritis (RA) defined by the
             1987-revised American College of Rheumatology (ACR) classification criteria and had
             disease duration of less than 1 year from diagnosis

          -  Subject must have a Disease Activity Score (DAS28, based on C-reactive protein)
             greater than 3.2, at least 6 swollen joints out of the 66 assessed, and at least 8
             tender joints out of the 68 assessed

          -  Subject must fulfill at least one of the following three criteria:

               -  Rheumatoid factor positive

               -  Greater than 1 joint erosion

               -  Anti-cyclic citrullinated peptide (CCP) antibody positive.

        Exclusion Criteria

          -  Subject has previously received systemic anti-tumor necrosis factor (TNF) therapy

          -  Subject has received any biologic or investigational therapy within 6 weeks prior to
             Baseline

          -  Subject has been previously treated with more than 2 disease-modifying antirheumatic
             drugs (DMARDs) or MTX, had been treated with intra-articular or parenteral
             administration of corticosteroids in preceding 4 weeks, or had undergone joint surgery
             within the preceding 2 months at joints to be assessed during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Redden, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4560</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4547</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-7201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6222</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4537</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6758</name>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 9323</name>
      <address>
        <city>Hemet</city>
        <state>California</state>
        <zip>92543</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4568</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037-0943</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4535</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4571</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 9271</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 10746</name>
      <address>
        <city>Victorville</city>
        <state>California</state>
        <zip>92395</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4559</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6229</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 10603</name>
      <address>
        <city>Lake Mary</city>
        <state>Florida</state>
        <zip>32746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 9325</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <zip>32073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4550</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4570</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4601</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4552</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 10745</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4548</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4557</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4605</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 10741</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6417</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4561</name>
      <address>
        <city>Dover</city>
        <state>New Hampshire</state>
        <zip>03820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 11222</name>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <zip>07728</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6228</name>
      <address>
        <city>Passaic</city>
        <state>New Jersey</state>
        <zip>07055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4544</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 12821</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4534</name>
      <address>
        <city>Orchard Park</city>
        <state>New York</state>
        <zip>14127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 9324</name>
      <address>
        <city>Plainview</city>
        <state>New York</state>
        <zip>11803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4600</name>
      <address>
        <city>Smithtown</city>
        <state>New York</state>
        <zip>11787</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4549</name>
      <address>
        <city>Mayfield Village</city>
        <state>Ohio</state>
        <zip>44143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6227</name>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <zip>97701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4546</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4564</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611-1124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4558</name>
      <address>
        <city>Wexford</city>
        <state>Pennsylvania</state>
        <zip>15090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4533</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7482</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 10743</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4562</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4536</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4538</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6899</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6381</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 10744</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4545</name>
      <address>
        <city>Glendale</city>
        <state>Wisconsin</state>
        <zip>53217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4572</name>
      <address>
        <city>Oak Creek</city>
        <state>Wisconsin</state>
        <zip>53154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3886</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1426AAL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3888</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1015ABO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6346</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1055AAF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3887</name>
      <address>
        <city>Quilmes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3889</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <zip>T4000AXL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8380</name>
      <address>
        <city>Campsie, Sydney</city>
        <zip>2194</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6954</name>
      <address>
        <city>Clayton</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6940</name>
      <address>
        <city>Malvern East</city>
        <zip>3145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3915</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3911</name>
      <address>
        <city>Graz</city>
        <zip>A-8020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3880</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3885</name>
      <address>
        <city>Vienna</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3916</name>
      <address>
        <city>Vienna</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7792</name>
      <address>
        <city>Vienna</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3914</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3909</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3881</name>
      <address>
        <city>Gilly</city>
        <zip>6060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3376</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6720</name>
      <address>
        <city>Mechelen</city>
        <zip>2800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6718</name>
      <address>
        <city>Sint-Niklaas</city>
        <zip>9100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3910</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6701</name>
      <address>
        <city>Burlington</city>
        <zip>L7R 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6834</name>
      <address>
        <city>Edmonton</city>
        <zip>T5M 0H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7197</name>
      <address>
        <city>Halifax</city>
        <zip>B3H 4K4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3883</name>
      <address>
        <city>Hamilton</city>
        <zip>L8N 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3884</name>
      <address>
        <city>Hamilton</city>
        <zip>L8N 2B6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3907</name>
      <address>
        <city>Montreal</city>
        <zip>H2L 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3903</name>
      <address>
        <city>Montreal</city>
        <zip>H3Z 2Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5178</name>
      <address>
        <city>Ottawa</city>
        <zip>K2G 6E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3904</name>
      <address>
        <city>Richmond</city>
        <zip>V7C 5L9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3912</name>
      <address>
        <city>Sainte-Foy, Quebec</city>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3901</name>
      <address>
        <city>Sarnia</city>
        <zip>N7T 5W6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3906</name>
      <address>
        <city>St. John's</city>
        <zip>A1A 5E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6542</name>
      <address>
        <city>Toronto</city>
        <zip>M9B 1B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3882</name>
      <address>
        <city>Victoria</city>
        <zip>V8V 3P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5616</name>
      <address>
        <city>Windsor</city>
        <zip>N8X 5A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5847</name>
      <address>
        <city>Winnipeg</city>
        <zip>R3A 1M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3905</name>
      <address>
        <city>Winnipeg</city>
        <zip>R3A 1M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3968</name>
      <address>
        <city>Brno</city>
        <zip>65691</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3971</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5559</name>
      <address>
        <city>Ostrava</city>
        <zip>72200</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3969</name>
      <address>
        <city>Prague 2</city>
        <zip>128 50</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5548</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>686 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3982</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3979</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3983</name>
      <address>
        <city>Paris Cedex 14</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3918</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3926</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>D-61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3928</name>
      <address>
        <city>Berlin-Buch</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3978</name>
      <address>
        <city>Damp</city>
        <zip>24351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3924</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3927</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3965</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3925</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4291</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8489</name>
      <address>
        <city>Hofheim</city>
        <zip>D-65719</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3923</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8483</name>
      <address>
        <city>Osnabrueck</city>
        <zip>D-49074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8486</name>
      <address>
        <city>Ratingen</city>
        <zip>40882</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3919</name>
      <address>
        <city>Vogelsang-Gommern</city>
        <zip>39245</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6637</name>
      <address>
        <city>Zerbst</city>
        <zip>39261</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3921</name>
      <address>
        <city>Budapest</city>
        <zip>1023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3922</name>
      <address>
        <city>Budapest</city>
        <zip>1277</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3920</name>
      <address>
        <city>Debrecen</city>
        <zip>4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3824</name>
      <address>
        <city>Aguascallentes</city>
        <zip>20230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3822</name>
      <address>
        <city>Leon, Guanajuato</city>
        <zip>37000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3825</name>
      <address>
        <city>Mexico City</city>
        <zip>10700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3951</name>
      <address>
        <city>Mexico City</city>
        <zip>10700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3890</name>
      <address>
        <city>Mexico City</city>
        <zip>14389</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3823</name>
      <address>
        <city>Mexico City</city>
        <zip>CP 1300</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3891</name>
      <address>
        <city>Mexico City</city>
        <zip>CP 14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3947</name>
      <address>
        <city>Arnem</city>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3948</name>
      <address>
        <city>Hilversum</city>
        <zip>1213XZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8485</name>
      <address>
        <city>Auckland 6</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8488</name>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8496</name>
      <address>
        <city>Timaru</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8511</name>
      <address>
        <city>Wellington</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7607</name>
      <address>
        <city>Alesund</city>
        <zip>N-6026</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7935</name>
      <address>
        <city>Kristiansand S</city>
        <zip>4615</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7506</name>
      <address>
        <city>Levanger</city>
        <zip>7600</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7511</name>
      <address>
        <city>Lillehammer</city>
        <zip>N-2609</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7500</name>
      <address>
        <city>Trondheim</city>
        <zip>N-7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3963</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3962</name>
      <address>
        <city>Katowice</city>
        <zip>40635</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5560</name>
      <address>
        <city>Lublin</city>
        <zip>20954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3961</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-342</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3944</name>
      <address>
        <city>Caguas</city>
        <zip>00725</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3937</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3934</name>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3935</name>
      <address>
        <city>San Juan</city>
        <zip>00936-5067</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3959</name>
      <address>
        <city>Piestany</city>
        <zip>92112</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3960</name>
      <address>
        <city>Piestany</city>
        <zip>92112</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7177</name>
      <address>
        <city>Berea, Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7175</name>
      <address>
        <city>Cape Town</city>
        <zip>7405</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7178</name>
      <address>
        <city>Cape Town</city>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7176</name>
      <address>
        <city>Port Elizabeth</city>
        <zip>6045</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7172</name>
      <address>
        <city>Pretoria</city>
        <zip>0028</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7174</name>
      <address>
        <city>Soweto</city>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3955</name>
      <address>
        <city>A Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 13661</name>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3930</name>
      <address>
        <city>Elche (Alicante)</city>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8524</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3956</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3943</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3931</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3957</name>
      <address>
        <city>Oviedo</city>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3954</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3932</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4015</name>
      <address>
        <city>Eskilstuna</city>
        <zip>SE-631 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3984</name>
      <address>
        <city>Falun</city>
        <zip>SE-79182</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4016</name>
      <address>
        <city>Malmoe</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4014</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4017</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4012</name>
      <address>
        <city>Bath</city>
        <zip>BA1 1RL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8495</name>
      <address>
        <city>Huddersfield</city>
        <zip>HD3 3EA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4048</name>
      <address>
        <city>Leeds</city>
        <zip>LS7 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4013</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4046</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4047</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 3985</name>
      <address>
        <city>Southampton</city>
        <zip>S016 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7977</name>
      <address>
        <city>York</city>
        <zip>YO31 8HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Greece</country>
  </removed_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2007</study_first_submitted>
  <study_first_submitted_qc>January 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2007</study_first_posted>
  <results_first_submitted>July 1, 2011</results_first_submitted>
  <results_first_submitted_qc>August 24, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 29, 2011</results_first_posted>
  <last_update_submitted>April 16, 2012</last_update_submitted>
  <last_update_submitted_qc>April 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Early Rheumatoid Arthritis</keyword>
  <keyword>Tumor Necrosis Factor Optimization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ADA+MTX</title>
          <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1</description>
        </group>
        <group group_id="P2">
          <title>PBO+MTX</title>
          <description>Methotrexate (MTX) monotherapy plus blinded placebo during Period 1</description>
        </group>
        <group group_id="P3">
          <title>ADA+MTX/PBO+MTX (Arm 1)</title>
          <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2</description>
        </group>
        <group group_id="P4">
          <title>ADA+MTX/ADA+MTX (Arm 2)</title>
          <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2</description>
        </group>
        <group group_id="P5">
          <title>ADA+MTX/OL ADA+MTX (Arm 3)</title>
          <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA and MTX during Period 2</description>
        </group>
        <group group_id="P6">
          <title>PBO+MTX/PBO+MTX (Arm 4)</title>
          <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2</description>
        </group>
        <group group_id="P7">
          <title>PBO+MTX/OL ADA+MTX (Arm 5)</title>
          <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="515"/>
                <participants group_id="P2" count="517"/>
                <participants group_id="P3" count="0">This treatment group is not relevant to Period 1.</participants>
                <participants group_id="P4" count="0">This treatment group is not relevant to Period 1.</participants>
                <participants group_id="P5" count="0">This treatment group is not relevant to Period 1.</participants>
                <participants group_id="P6" count="0">This treatment group is not relevant to Period 1.</participants>
                <participants group_id="P7" count="0">This treatment group is not relevant to Period 1.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="466"/>
                <participants group_id="P2" count="460"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of efficacy/Loss of efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject moved/relocated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliant with study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomization error</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Suspected tuberculosis/positive test</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study site closure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject received new diagnosis</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Received wrong treatment/incorrect dose</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to meet entry criteria</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Took prohibited medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">This treatment group is not relevant to Period 2.</participants>
                <participants group_id="P2" count="0">This treatment group is not relevant to Period 2.</participants>
                <participants group_id="P3" count="102"/>
                <participants group_id="P4" count="105"/>
                <participants group_id="P5" count="259"/>
                <participants group_id="P6" count="112"/>
                <participants group_id="P7" count="348"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="89"/>
                <participants group_id="P4" count="95"/>
                <participants group_id="P5" count="216"/>
                <participants group_id="P6" count="97"/>
                <participants group_id="P7" count="295"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="43"/>
                <participants group_id="P6" count="15"/>
                <participants group_id="P7" count="53"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of efficacy/Loss of efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Received wrong treatment/incorrect dose</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject unable to find transportation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomization error</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliant with study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Methotrexate intolerance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Took prohibited medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ADA+MTX</title>
          <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1</description>
        </group>
        <group group_id="B2">
          <title>PBO+MTX</title>
          <description>Methotrexate (MTX) monotherapy plus blinded placebo(PBO) during Period 1</description>
        </group>
        <group group_id="B3">
          <title>ADA+MTX/PBO+MTX (Arm 1)</title>
          <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA)during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2</description>
        </group>
        <group group_id="B4">
          <title>ADA+MTX/ADA+MTX (Arm 2)</title>
          <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2</description>
        </group>
        <group group_id="B5">
          <title>ADA+MTX/OL ADA+MTX (Arm 3)</title>
          <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA and MTX during Period 2</description>
        </group>
        <group group_id="B6">
          <title>PBO+MTX/PBO+MTX (Arm 4)</title>
          <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2</description>
        </group>
        <group group_id="B7">
          <title>PBO+MTX/OL ADA+MTX (Arm 5)</title>
          <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="515"/>
            <count group_id="B2" value="517"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="0"/>
            <count group_id="B5" value="0"/>
            <count group_id="B6" value="0"/>
            <count group_id="B7" value="0"/>
            <count group_id="B8" value="1032"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="418"/>
                    <measurement group_id="B2" value="431"/>
                    <measurement group_id="B8" value="849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B8" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.7" spread="14.48"/>
                    <measurement group_id="B2" value="50.4" spread="13.62"/>
                    <measurement group_id="B8" value="50.6" spread="14.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="380"/>
                    <measurement group_id="B2" value="382"/>
                    <measurement group_id="B8" value="762"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B8" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B8" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B8" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B8" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B8" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B8" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B8" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B8" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B8" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B8" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B8" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Norway</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B8" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B8" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B8" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B8" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B8" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B8" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B8" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B8" value="301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Low Disease Activity (DAS28 Less Than 3.2) and No Radiographic Progression From Baseline (Change in mTSS Less Than or Equal to 0.5) at Week 78, Arm 2 vs. Arm 4</title>
        <description>The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07, with scores below 3.2 indicating low disease activity. For the modified Total Sharp score (mTSS), x-rays of hand/wrist and feet joints are scored for erosions (0 to 5) and joint space narrowing (0 to 4). The erosion score and the narrowing score are added to determine the total score, which ranges from 0 (no damage) to 448.</description>
        <time_frame>Week 78</time_frame>
        <population>The analysis was performed on the ITT Population comprised of all subjects who entered Period 2 and received at least 1 dose of study drug (blinded or open-label) during Period 2. Nonresponder imputation was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA+MTX/PBO+MTX (Arm 1)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA)during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2</description>
          </group>
          <group group_id="O2">
            <title>ADA+MTX/ADA+MTX (Arm 2)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2</description>
          </group>
          <group group_id="O3">
            <title>ADA+MTX/OL ADA+MTX (Arm 3)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA and MTX during Period 2</description>
          </group>
          <group group_id="O4">
            <title>PBO+MTX/PBO+MTX (Arm 4)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2</description>
          </group>
          <group group_id="O5">
            <title>PBO+MTX/OL ADA+MTX (Arm 5)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Low Disease Activity (DAS28 Less Than 3.2) and No Radiographic Progression From Baseline (Change in mTSS Less Than or Equal to 0.5) at Week 78, Arm 2 vs. Arm 4</title>
          <description>The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07, with scores below 3.2 indicating low disease activity. For the modified Total Sharp score (mTSS), x-rays of hand/wrist and feet joints are scored for erosions (0 to 5) and joint space narrowing (0 to 4). The erosion score and the narrowing score are added to determine the total score, which ranges from 0 (no damage) to 448.</description>
          <population>The analysis was performed on the ITT Population comprised of all subjects who entered Period 2 and received at least 1 dose of study drug (blinded or open-label) during Period 2. Nonresponder imputation was used for missing data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="259"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="61"/>
                    <measurement group_id="O5" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>Chi-squared</method>
            <method_desc>P value is from Pearson's chi-square test.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Low Disease Activity (DAS28 Less Than 3.2) and No Radiographic Progression From Baseline (Change in mTSS Less Than or Equal to 0.5) at Week 78, Arm 2 vs. Arm 1</title>
        <description>The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07, with scores below 3.2 indicating low disease activity. For the modified Total Sharp score (mTSS), x-rays of hand/wrist and feet joints are scored for erosions (0 to 5) and joint space narrowing (0 to 4). The erosion score and the narrowing score are added to determine the total score, which ranges from 0 (no damage) to 448.</description>
        <time_frame>Week 78</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ADA+MTX/PBO+MTX (Arm 1)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA)during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2</description>
          </group>
          <group group_id="O2">
            <title>ADA+MTX/ADA+MTX (Arm 2)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2</description>
          </group>
          <group group_id="O3">
            <title>ADA+MTX/OL ADA+MTX (Arm 3)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA and MTX during Period 2</description>
          </group>
          <group group_id="O4">
            <title>PBO+MTX/PBO+MTX (Arm 4)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2</description>
          </group>
          <group group_id="O5">
            <title>PBO+MTX/OL ADA+MTX (Arm 5)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Low Disease Activity (DAS28 Less Than 3.2) and No Radiographic Progression From Baseline (Change in mTSS Less Than or Equal to 0.5) at Week 78, Arm 2 vs. Arm 1</title>
          <description>The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07, with scores below 3.2 indicating low disease activity. For the modified Total Sharp score (mTSS), x-rays of hand/wrist and feet joints are scored for erosions (0 to 5) and joint space narrowing (0 to 4). The erosion score and the narrowing score are added to determine the total score, which ranges from 0 (no damage) to 448.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="259"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="61"/>
                    <measurement group_id="O5" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.082</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With DAS28 Low Disease Activity (DAS28 Less Than 3.2) at Week 78</title>
        <description>The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07. A DAS28 less than 2.6 indicates clinical remission, DAS28 2.6 to 3.2 indicates low disease activity, DAS28 3.2 to less than 5.1 indicates moderate disease activity, and DAS28 of 5.1 or greater indicates high disease activity.</description>
        <time_frame>Week 78</time_frame>
        <population>ITT Population, Nonresponder imputation</population>
        <group_list>
          <group group_id="O1">
            <title>ADA+MTX/PBO+MTX (Arm 1)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA)during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2</description>
          </group>
          <group group_id="O2">
            <title>ADA+MTX/ADA+MTX (Arm 2)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2</description>
          </group>
          <group group_id="O3">
            <title>ADA+MTX/OL ADA+MTX (Arm 3)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA and MTX during Period 2</description>
          </group>
          <group group_id="O4">
            <title>PBO+MTX/PBO+MTX (Arm 4)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2</description>
          </group>
          <group group_id="O5">
            <title>PBO+MTX/OL ADA+MTX (Arm 5)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With DAS28 Low Disease Activity (DAS28 Less Than 3.2) at Week 78</title>
          <description>The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07. A DAS28 less than 2.6 indicates clinical remission, DAS28 2.6 to 3.2 indicates low disease activity, DAS28 3.2 to less than 5.1 indicates moderate disease activity, and DAS28 of 5.1 or greater indicates high disease activity.</description>
          <population>ITT Population, Nonresponder imputation</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="259"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="108"/>
                    <measurement group_id="O4" value="78"/>
                    <measurement group_id="O5" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.280</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.287</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With DAS28 Remission (DAS28 Less Than 2.6) at Week 78</title>
        <description>The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07. A DAS28 less than 2.6 indicates clinical remission, DAS28 2.6 to 3.2 indicates low disease activity, DAS28 3.2 to less than 5.1 indicates moderate disease activity, and DAS28 of 5.1 or greater indicates high disease activity.</description>
        <time_frame>Week 78</time_frame>
        <population>ITT Population, nonresponder imputation</population>
        <group_list>
          <group group_id="O1">
            <title>ADA+MTX/PBO+MTX (Arm 1)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA)during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2</description>
          </group>
          <group group_id="O2">
            <title>ADA+MTX/ADA+MTX (Arm 2)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2</description>
          </group>
          <group group_id="O3">
            <title>ADA+MTX/OL ADA+MTX (Arm 3)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA and MTX during Period 2</description>
          </group>
          <group group_id="O4">
            <title>PBO+MTX/PBO+MTX (Arm 4)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2</description>
          </group>
          <group group_id="O5">
            <title>PBO+MTX/OL ADA+MTX (Arm 5)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With DAS28 Remission (DAS28 Less Than 2.6) at Week 78</title>
          <description>The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07. A DAS28 less than 2.6 indicates clinical remission, DAS28 2.6 to 3.2 indicates low disease activity, DAS28 3.2 to less than 5.1 indicates moderate disease activity, and DAS28 of 5.1 or greater indicates high disease activity.</description>
          <population>ITT Population, nonresponder imputation</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="259"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="66"/>
                    <measurement group_id="O5" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.026</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS Less Than or Equal to 0.5) at Week 78</title>
        <description>For the modified Total Sharp score (mTSS), x-rays of hand/wrist and feet joints are scored for erosions (0 to 5) and joint space narrowing (0 to 4). The erosion score and the narrowing score are added to determine the total score, which ranges from 0 (no damage) to 448. An increase in mTSS from baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.</description>
        <time_frame>Week 78</time_frame>
        <population>ITT Population, nonresponder imputation</population>
        <group_list>
          <group group_id="O1">
            <title>ADA+MTX/PBO+MTX (Arm 1)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA)during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2</description>
          </group>
          <group group_id="O2">
            <title>ADA+MTX/ADA+MTX (Arm 2)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2</description>
          </group>
          <group group_id="O3">
            <title>ADA+MTX/OL ADA+MTX (Arm 3)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA and MTX during Period 2</description>
          </group>
          <group group_id="O4">
            <title>PBO+MTX/PBO+MTX (Arm 4)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2</description>
          </group>
          <group group_id="O5">
            <title>PBO+MTX/OL ADA+MTX (Arm 5)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS Less Than or Equal to 0.5) at Week 78</title>
          <description>For the modified Total Sharp score (mTSS), x-rays of hand/wrist and feet joints are scored for erosions (0 to 5) and joint space narrowing (0 to 4). The erosion score and the narrowing score are added to determine the total score, which ranges from 0 (no damage) to 448. An increase in mTSS from baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.</description>
          <population>ITT Population, nonresponder imputation</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="259"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="182"/>
                    <measurement group_id="O4" value="77"/>
                    <measurement group_id="O5" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.060</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.063</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 78</title>
        <description>Subjects were responders if they had greater than or equal to 20% improvement in tender joint count; greater than or equal to 20% improvement in swollen joint count; and greater than or equal to 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and acute phase reactant (C-reactive protein).</description>
        <time_frame>Week 78</time_frame>
        <population>ITT Population, nonresponder imputation</population>
        <group_list>
          <group group_id="O1">
            <title>ADA+MTX/PBO+MTX (Arm 1)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA)during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2</description>
          </group>
          <group group_id="O2">
            <title>ADA+MTX/ADA+MTX (Arm 2)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2</description>
          </group>
          <group group_id="O3">
            <title>ADA+MTX/OL ADA+MTX (Arm 3)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA and MTX during Period 2</description>
          </group>
          <group group_id="O4">
            <title>PBO+MTX/PBO+MTX (Arm 4)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2</description>
          </group>
          <group group_id="O5">
            <title>PBO+MTX/OL ADA+MTX (Arm 5)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 78</title>
          <description>Subjects were responders if they had greater than or equal to 20% improvement in tender joint count; greater than or equal to 20% improvement in swollen joint count; and greater than or equal to 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and acute phase reactant (C-reactive protein).</description>
          <population>ITT Population, nonresponder imputation</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="259"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="172"/>
                    <measurement group_id="O4" value="90"/>
                    <measurement group_id="O5" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.395</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.640</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 78</title>
        <description>Subjects were responders if they had: greater than or equal to 50% improvement in tender joint count; greater than or equal to 50% improvement in swollen joint count; and greater than or equal to 50% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and acute phase reactant (C-reactive protein).</description>
        <time_frame>Week 78</time_frame>
        <population>ITT Population, nonresponder imputation</population>
        <group_list>
          <group group_id="O1">
            <title>ADA+MTX/PBO+MTX (Arm 1)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA)during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2</description>
          </group>
          <group group_id="O2">
            <title>ADA+MTX/ADA+MTX (Arm 2)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2</description>
          </group>
          <group group_id="O3">
            <title>ADA+MTX/OL ADA+MTX (Arm 3)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA and MTX during Period 2</description>
          </group>
          <group group_id="O4">
            <title>PBO+MTX/PBO+MTX (Arm 4)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2</description>
          </group>
          <group group_id="O5">
            <title>PBO+MTX/OL ADA+MTX (Arm 5)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 78</title>
          <description>Subjects were responders if they had: greater than or equal to 50% improvement in tender joint count; greater than or equal to 50% improvement in swollen joint count; and greater than or equal to 50% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and acute phase reactant (C-reactive protein).</description>
          <population>ITT Population, nonresponder imputation</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="259"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="120"/>
                    <measurement group_id="O4" value="78"/>
                    <measurement group_id="O5" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.159</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.217</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Meeting American College of Rheumatology 70% (ACR70) Response Criteria at Week 78</title>
        <description>Subjects were responders if they had: greater than or equal to 70% improvement in tender joint count; greater than or equal to 70% improvement in swollen joint count; and greater than or equal to 70% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and acute phase reactant (C-reactive protein).</description>
        <time_frame>Week 78</time_frame>
        <population>ITT Population, nonresponder imputation</population>
        <group_list>
          <group group_id="O1">
            <title>ADA+MTX/PBO+MTX (Arm 1)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA)during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2</description>
          </group>
          <group group_id="O2">
            <title>ADA+MTX/ADA+MTX (Arm 2)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2</description>
          </group>
          <group group_id="O3">
            <title>ADA+MTX/OL ADA+MTX (Arm 3)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA and MTX during Period 2</description>
          </group>
          <group group_id="O4">
            <title>PBO+MTX/PBO+MTX (Arm 4)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2</description>
          </group>
          <group group_id="O5">
            <title>PBO+MTX/OL ADA+MTX (Arm 5)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Meeting American College of Rheumatology 70% (ACR70) Response Criteria at Week 78</title>
          <description>Subjects were responders if they had: greater than or equal to 70% improvement in tender joint count; greater than or equal to 70% improvement in swollen joint count; and greater than or equal to 70% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and acute phase reactant (C-reactive protein).</description>
          <population>ITT Population, nonresponder imputation</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="259"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="78"/>
                    <measurement group_id="O4" value="64"/>
                    <measurement group_id="O5" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.060</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.043</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DAS28 Score at Week 78</title>
        <description>The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07. A DAS28 less than 2.6 indicates clinical remission, DAS28 2.6 to 3.2 indicates low disease activity, DAS28 3.2 to less than 5.1 indicates moderate disease activity, and DAS28 of 5.1 or greater indicates high disease activity.</description>
        <time_frame>Baseline to Week 78</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ADA+MTX/PBO+MTX (Arm 1)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA)during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2</description>
          </group>
          <group group_id="O2">
            <title>ADA+MTX/ADA+MTX (Arm 2)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2</description>
          </group>
          <group group_id="O3">
            <title>ADA+MTX/OL ADA+MTX (Arm 3)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA and MTX during Period 2</description>
          </group>
          <group group_id="O4">
            <title>PBO+MTX/PBO+MTX (Arm 4)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2</description>
          </group>
          <group group_id="O5">
            <title>PBO+MTX/OL ADA+MTX (Arm 5)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28 Score at Week 78</title>
          <description>The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07. A DAS28 less than 2.6 indicates clinical remission, DAS28 2.6 to 3.2 indicates low disease activity, DAS28 3.2 to less than 5.1 indicates moderate disease activity, and DAS28 of 5.1 or greater indicates high disease activity.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="259"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.54" spread="1.259"/>
                    <measurement group_id="O2" value="-3.71" spread="1.134"/>
                    <measurement group_id="O3" value="-2.70" spread="1.531"/>
                    <measurement group_id="O4" value="-3.04" spread="1.513"/>
                    <measurement group_id="O5" value="-3.07" spread="1.486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance adjusting for baseline</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.049</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance adjusting for baseline</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Clinical Disease Activity Index (CDAI) Low Disease Activity (CDAI Less Than or Equal to 10) at Week 78</title>
        <description>The CDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, and physician's global assessment of disease activity. Scores range from 0 to 76.0, with a higher score reflecting worsening disease.</description>
        <time_frame>Week 78</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ADA+MTX/PBO+MTX (Arm 1)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA)during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2</description>
          </group>
          <group group_id="O2">
            <title>ADA+MTX/ADA+MTX (Arm 2)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2</description>
          </group>
          <group group_id="O3">
            <title>ADA+MTX/OL ADA+MTX (Arm 3)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA and MTX during Period 2</description>
          </group>
          <group group_id="O4">
            <title>PBO+MTX/PBO+MTX (Arm 4)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2</description>
          </group>
          <group group_id="O5">
            <title>PBO+MTX/OL ADA+MTX (Arm 5)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Clinical Disease Activity Index (CDAI) Low Disease Activity (CDAI Less Than or Equal to 10) at Week 78</title>
          <description>The CDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, and physician's global assessment of disease activity. Scores range from 0 to 76.0, with a higher score reflecting worsening disease.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="259"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="109"/>
                    <measurement group_id="O4" value="82"/>
                    <measurement group_id="O5" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.240</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.271</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Simplified Disease Activity Index (SDAI) Low Disease Activity (SDAI Less Than or Equal to 11) at Week 78</title>
        <description>The SDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, physician's global assessment of disease activity, and acute phase reactant (C-reactive protein). Scores range from 0.1 to 86.0, with a higher score reflecting worsening disease.</description>
        <time_frame>Week 78</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ADA+MTX/PBO+MTX (Arm 1)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA)during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2</description>
          </group>
          <group group_id="O2">
            <title>ADA+MTX/ADA+MTX (Arm 2)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2</description>
          </group>
          <group group_id="O3">
            <title>ADA+MTX/OL ADA+MTX (Arm 3)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA and MTX during Period 2</description>
          </group>
          <group group_id="O4">
            <title>PBO+MTX/PBO+MTX (Arm 4)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2</description>
          </group>
          <group group_id="O5">
            <title>PBO+MTX/OL ADA+MTX (Arm 5)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Simplified Disease Activity Index (SDAI) Low Disease Activity (SDAI Less Than or Equal to 11) at Week 78</title>
          <description>The SDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, physician's global assessment of disease activity, and acute phase reactant (C-reactive protein). Scores range from 0.1 to 86.0, with a higher score reflecting worsening disease.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="259"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="106"/>
                    <measurement group_id="O4" value="76"/>
                    <measurement group_id="O5" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.230</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.550</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Clinical Disease Activity Index (CDAI) Remission (CDAI Less Than or Equal to 2.8) at Week 78</title>
        <description>The CDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, and physician's global assessment of disease activity. Scores range from 0 to 76.0, with a higher score reflecting worsening disease.</description>
        <time_frame>Week 78</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ADA+MTX/PBO+MTX (Arm 1)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA)during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2</description>
          </group>
          <group group_id="O2">
            <title>ADA+MTX/ADA+MTX (Arm 2)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2</description>
          </group>
          <group group_id="O3">
            <title>ADA+MTX/OL ADA+MTX (Arm 3)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA and MTX during Period 2</description>
          </group>
          <group group_id="O4">
            <title>PBO+MTX/PBO+MTX (Arm 4)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2</description>
          </group>
          <group group_id="O5">
            <title>PBO+MTX/OL ADA+MTX (Arm 5)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Clinical Disease Activity Index (CDAI) Remission (CDAI Less Than or Equal to 2.8) at Week 78</title>
          <description>The CDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, and physician's global assessment of disease activity. Scores range from 0 to 76.0, with a higher score reflecting worsening disease.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="259"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="54"/>
                    <measurement group_id="O5" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.301</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.188</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Simplified Disease Activity Index (SDAI) Remission (SDAI Less Than or Equal to 3.3) at Week 78</title>
        <description>The SDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, physician's global assessment of disease activity, and acute phase reactant (C-reactive protein). Scores range from 0.1 to 86.0, with a higher score reflecting worsening disease.</description>
        <time_frame>Week 78</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ADA+MTX/PBO+MTX (Arm 1)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA)during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2</description>
          </group>
          <group group_id="O2">
            <title>ADA+MTX/ADA+MTX (Arm 2)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2</description>
          </group>
          <group group_id="O3">
            <title>ADA+MTX/OL ADA+MTX (Arm 3)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA and MTX during Period 2</description>
          </group>
          <group group_id="O4">
            <title>PBO+MTX/PBO+MTX (Arm 4)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2</description>
          </group>
          <group group_id="O5">
            <title>PBO+MTX/OL ADA+MTX (Arm 5)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Simplified Disease Activity Index (SDAI) Remission (SDAI Less Than or Equal to 3.3) at Week 78</title>
          <description>The SDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, physician's global assessment of disease activity, and acute phase reactant (C-reactive protein). Scores range from 0.1 to 86.0, with a higher score reflecting worsening disease.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="259"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="51"/>
                    <measurement group_id="O5" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.314</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.235</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CDAI Score at Week 78</title>
        <description>The CDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, and physician's global assessment of disease activity. Scores range from 0 to 76.0, with a higher score reflecting worsening disease.</description>
        <time_frame>Baseline to Week 78</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ADA+MTX/PBO+MTX (Arm 1)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA)during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2</description>
          </group>
          <group group_id="O2">
            <title>ADA+MTX/ADA+MTX (Arm 2)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2</description>
          </group>
          <group group_id="O3">
            <title>ADA+MTX/OL ADA+MTX (Arm 3)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA and MTX during Period 2</description>
          </group>
          <group group_id="O4">
            <title>PBO+MTX/PBO+MTX (Arm 4)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2</description>
          </group>
          <group group_id="O5">
            <title>PBO+MTX/OL ADA+MTX (Arm 5)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CDAI Score at Week 78</title>
          <description>The CDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, and physician's global assessment of disease activity. Scores range from 0 to 76.0, with a higher score reflecting worsening disease.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="259"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.30" spread="12.808"/>
                    <measurement group_id="O2" value="-33.29" spread="12.964"/>
                    <measurement group_id="O3" value="-29.06" spread="16.561"/>
                    <measurement group_id="O4" value="-27.63" spread="15.526"/>
                    <measurement group_id="O5" value="-31.30" spread="14.769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.030</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance adjusting for baseline</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.403</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance adjusting for baseline</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SDAI Score at Week 78</title>
        <description>The SDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, physician's global assessment of disease activity, and acute phase reactant (C-reactive protein). Scores range from 0.1 to 86.0, with a higher score reflecting worsening disease.</description>
        <time_frame>Baseline to Week 78</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ADA+MTX/PBO+MTX (Arm 1)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA)during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2</description>
          </group>
          <group group_id="O2">
            <title>ADA+MTX/ADA+MTX (Arm 2)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2</description>
          </group>
          <group group_id="O3">
            <title>ADA+MTX/OL ADA+MTX (Arm 3)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA and MTX during Period 2</description>
          </group>
          <group group_id="O4">
            <title>PBO+MTX/PBO+MTX (Arm 4)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2</description>
          </group>
          <group group_id="O5">
            <title>PBO+MTX/OL ADA+MTX (Arm 5)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SDAI Score at Week 78</title>
          <description>The SDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, physician's global assessment of disease activity, and acute phase reactant (C-reactive protein). Scores range from 0.1 to 86.0, with a higher score reflecting worsening disease.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="259"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.61" spread="13.527"/>
                    <measurement group_id="O2" value="-35.16" spread="13.784"/>
                    <measurement group_id="O3" value="-31.00" spread="17.856"/>
                    <measurement group_id="O4" value="-29.30" spread="17.120"/>
                    <measurement group_id="O5" value="-33.43" spread="15.852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.036</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance adjusting for baseline</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.349</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance adjusting for baseline</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Synovitis Score According to the Rheumatoid Arthritis Magnetic Resonance Imaging (RA MRI) Scoring System (RAMRIS) at Week 78</title>
        <description>Synovitis was assessed using high-field magnetic resonance imaging (MRI) of the hand and wrist. Images were read and scored according to the Outcomes Measures in Rheumatology Clinical Trials' Rheumatoid Arthritis MRI Scoring System (OMERACT RAMRIS). Synovitis in the wrist and finger joints in the most affected hand was scored from 0 (normal) to 3 (severe), for a maximum total score of 21.</description>
        <time_frame>Baseline to Week 78</time_frame>
        <population>The analysis is based on the Primary Analysis Set, a subset of the ITT Analysis Set that includes subjects who participated in the 78-week HF MRI substudy and whose Baseline HF MRI data were collected on or before the first study drug dose. Observed scores are used in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA+MTX/PBO+MTX (Arm 1)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA)during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2</description>
          </group>
          <group group_id="O2">
            <title>ADA+MTX/ADA+MTX (Arm 2)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2</description>
          </group>
          <group group_id="O3">
            <title>ADA+MTX/OL ADA+MTX (Arm 3)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA and MTX during Period 2</description>
          </group>
          <group group_id="O4">
            <title>PBO+MTX/PBO+MTX (Arm 4)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2</description>
          </group>
          <group group_id="O5">
            <title>PBO+MTX/OL ADA+MTX (Arm 5)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Synovitis Score According to the Rheumatoid Arthritis Magnetic Resonance Imaging (RA MRI) Scoring System (RAMRIS) at Week 78</title>
          <description>Synovitis was assessed using high-field magnetic resonance imaging (MRI) of the hand and wrist. Images were read and scored according to the Outcomes Measures in Rheumatology Clinical Trials' Rheumatoid Arthritis MRI Scoring System (OMERACT RAMRIS). Synovitis in the wrist and finger joints in the most affected hand was scored from 0 (normal) to 3 (severe), for a maximum total score of 21.</description>
          <population>The analysis is based on the Primary Analysis Set, a subset of the ITT Analysis Set that includes subjects who participated in the 78-week HF MRI substudy and whose Baseline HF MRI data were collected on or before the first study drug dose. Observed scores are used in the analysis.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="2.121"/>
                    <measurement group_id="O2" value="-3.38" spread="2.562"/>
                    <measurement group_id="O3" value="-3.25" spread="3.631"/>
                    <measurement group_id="O4" value="-3.88" spread="3.351"/>
                    <measurement group_id="O5" value="-4.27" spread="4.211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.037</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance adjusting for baseline</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance adjusting for baseline</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5) and Normal Function (HAQ-DI Less Than 0.5) at Week 78</title>
        <description>In the Health Assessment Questionnaire Disability Index (HAQ-DI), participants rated their ability to perform daily tasks on a scale of 0 (without any difficulty) to 3 (unable to do). A mean score of 0-1 represents mild to moderate functional disability, 1-2 represents moderate to severe, 2-3 severe to very severe disability. For the modified Total Sharp score (mTSS), x-rays of hand/wrist and feet joints are scored for erosions (0 to 5) and joint space narrowing (0 to 4). The erosion score and the narrowing score are added to determine the total score, which ranges from 0 (no damage) to 448.</description>
        <time_frame>Week 78</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ADA+MTX/PBO+MTX (Arm 1)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA)during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2</description>
          </group>
          <group group_id="O2">
            <title>ADA+MTX/ADA+MTX (Arm 2)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2</description>
          </group>
          <group group_id="O3">
            <title>ADA+MTX/OL ADA+MTX (Arm 3)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA and MTX during Period 2</description>
          </group>
          <group group_id="O4">
            <title>PBO+MTX/PBO+MTX (Arm 4)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2</description>
          </group>
          <group group_id="O5">
            <title>PBO+MTX/OL ADA+MTX (Arm 5)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5) and Normal Function (HAQ-DI Less Than 0.5) at Week 78</title>
          <description>In the Health Assessment Questionnaire Disability Index (HAQ-DI), participants rated their ability to perform daily tasks on a scale of 0 (without any difficulty) to 3 (unable to do). A mean score of 0-1 represents mild to moderate functional disability, 1-2 represents moderate to severe, 2-3 severe to very severe disability. For the modified Total Sharp score (mTSS), x-rays of hand/wrist and feet joints are scored for erosions (0 to 5) and joint space narrowing (0 to 4). The erosion score and the narrowing score are added to determine the total score, which ranges from 0 (no damage) to 448.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="259"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="65"/>
                    <measurement group_id="O4" value="53"/>
                    <measurement group_id="O5" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.192</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.241</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5), Normal Function (HAQ-DI Less Than or Equal to 0.5), and ACR70 Response at Week 78</title>
        <description>In the Health Assessment Questionnaire Disability Index (HAQ-DI), a score of 0-1 represents mild to moderate, 1-2 moderate to severe, 2-3 severe to very severe disability. The modified Total Sharp score (mTSS) ranges from 0 (no joint damage) to 448 (worst joint damage). American College of Rheumatology 70% (ACR70) response indicates at least 70% improvement in tender and swollen joint counts and at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; HAQ-DI; and C-reactive protein.</description>
        <time_frame>Week 78</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ADA+MTX/PBO+MTX (Arm 1)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA)during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2</description>
          </group>
          <group group_id="O2">
            <title>ADA+MTX/ADA+MTX (Arm 2)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2</description>
          </group>
          <group group_id="O3">
            <title>ADA+MTX/OL ADA+MTX (Arm 3)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA and MTX during Period 2</description>
          </group>
          <group group_id="O4">
            <title>PBO+MTX/PBO+MTX (Arm 4)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2</description>
          </group>
          <group group_id="O5">
            <title>PBO+MTX/OL ADA+MTX (Arm 5)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5), Normal Function (HAQ-DI Less Than or Equal to 0.5), and ACR70 Response at Week 78</title>
          <description>In the Health Assessment Questionnaire Disability Index (HAQ-DI), a score of 0-1 represents mild to moderate, 1-2 moderate to severe, 2-3 severe to very severe disability. The modified Total Sharp score (mTSS) ranges from 0 (no joint damage) to 448 (worst joint damage). American College of Rheumatology 70% (ACR70) response indicates at least 70% improvement in tender and swollen joint counts and at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; HAQ-DI; and C-reactive protein.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="259"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="43"/>
                    <measurement group_id="O5" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.028</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5), Normal Function (HAQ-DI Less Than 0.5), and DAS28 Remission (DAS28 Less Than 2.6) at Week 78</title>
        <description>In the Health Assessment Questionnaire Disability Index (HAQ-DI), a score of 0-1 represents mild to moderate, 1-2 moderate to severe, 2-3 severe to very severe disability. The modified Total Sharp score (mTSS) ranges from 0 (no joint damage) to 448 (severe joint damage). The Disease Activity Score (DAS28) ranges from 0.49 to 9.07, with scores less than 2.6 indicating clinical remission.</description>
        <time_frame>Week 78</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ADA+MTX/PBO+MTX (Arm 1)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA)during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2</description>
          </group>
          <group group_id="O2">
            <title>ADA+MTX/ADA+MTX (Arm 2)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2</description>
          </group>
          <group group_id="O3">
            <title>ADA+MTX/OL ADA+MTX (Arm 3)</title>
            <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA and MTX during Period 2</description>
          </group>
          <group group_id="O4">
            <title>PBO+MTX/PBO+MTX (Arm 4)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2</description>
          </group>
          <group group_id="O5">
            <title>PBO+MTX/OL ADA+MTX (Arm 5)</title>
            <description>Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5), Normal Function (HAQ-DI Less Than 0.5), and DAS28 Remission (DAS28 Less Than 2.6) at Week 78</title>
          <description>In the Health Assessment Questionnaire Disability Index (HAQ-DI), a score of 0-1 represents mild to moderate, 1-2 moderate to severe, 2-3 severe to very severe disability. The modified Total Sharp score (mTSS) ranges from 0 (no joint damage) to 448 (severe joint damage). The Disease Activity Score (DAS28) ranges from 0.49 to 9.07, with scores less than 2.6 indicating clinical remission.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="259"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="43"/>
                    <measurement group_id="O5" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.074</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.077</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events reported during Period 1 (Weeks 0 to 26) are presented by Period 1 treatment group. Adverse events reported during Period 2 (Weeks 26 to 78) are presented by Period 2 treatment arm (Arm 1 through Arm 5).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ADA+MTX/PBO+MTX (Arm 1)</title>
          <description>Blinded combination ADA+MTX therapy during Period 1 and blinded MTX monotherapy during Period 2</description>
        </group>
        <group group_id="E2">
          <title>ADA+MTX/ADA+MTX (Arm 2)</title>
          <description>Blinded combination ADA+MTX therapy during Period 1 and Period 2</description>
        </group>
        <group group_id="E3">
          <title>ADA+MTX/OL ADA+MTX (Arm 3)</title>
          <description>Blinded combination therapy during Period 1, open-label combination therapy during Period 2</description>
        </group>
        <group group_id="E4">
          <title>PBO+MTX/PBO+MTX (Arm 4)</title>
          <description>Blinded MTX monotherapy during Period 1 and Period 2</description>
        </group>
        <group group_id="E5">
          <title>PBO+MTX/OL ADA+MTX (Arm 5)</title>
          <description>Blinded MTX monotherapy during Period 1, open-label combination therapy during Period 2</description>
        </group>
        <group group_id="E6">
          <title>Period 1 ADA+MTX</title>
          <description>Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1</description>
        </group>
        <group group_id="E7">
          <title>Period 1 PBO+MTX</title>
          <description>Combination therapy with methotrexate (MTX) and blinded placebo (PBO) during Period 1</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="32" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="37" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="32" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <description>Adverse event resulted in death of subject</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Microgenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Gastric dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Oedematous pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Oesophageal achalasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Drug intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Ischaemic hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Atypical mycobacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <description>Adverse event resulted in death of subject</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Candida sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Peritoneal tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Adverse event resulted in death of 1 subject in Arm 5</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Vulvovaginitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Kidney rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Vaccination complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Knee deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Monarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Osteoporotic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Benign mediastinal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Oesophageal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Facial palsy</sub_title>
                <description>Adverse event resulted in death of subject, who also had a fatal adverse event of confusional state (cause of death possibly cerebrovascular accident)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute stress disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <description>Adverse event resulted in death of subject, who also had a fatal adverse event of facial palsy (cause of death possibly cerebrovascular accident)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Micromastia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <description>Adverse event resulted in death of subject</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Alveolitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <description>Adverse event resulted in death of 2 subjects in ADA+MTX group during Period 1</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Physical abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="106" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="134" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="149" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="128" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="27" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="60" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="55" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="34" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="25" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="35" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="38" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="25" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="22" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="26" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="24" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="259"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="348"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="515"/>
                <counts group_id="E7" subjects_affected="19" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any investigator or institution that plans on presenting/publishing results disclosure, should provide written notification to Abbott within 60 days of their presentation/publication. Abbott requests that no presentation/publication will be allowed until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay of any proposed presentation/publication maybe requested if Abbott needs to secure patent or other proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>Abbott</organization>
      <phone>1-800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

